Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
42,194,093
-
Total 13F shares
-
20,057,814
-
Share change
-
-473,331
-
Total reported value
-
$252,130,286
-
Put/Call ratio
-
480%
-
Price per share
-
$12.57
-
Number of holders
-
73
-
Value change
-
-$6,024,605
-
Number of buys
-
37
-
Number of sells
-
24
Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) as of Q1 2023
As of 31 Mar 2023,
Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) was held by
73 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,057,814 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, Vivo Capital, LLC, TANG CAPITAL MANAGEMENT LLC, Frazier Life Sciences Management, L.P., BlackRock Inc., Cormorant Asset Management, LP, PERCEPTIVE ADVISORS LLC, VANGUARD GROUP INC, TimesSquare Capital Management, LLC, and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C).
This page lists
73
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.